Echo Therapeutics, Inc. (ECTE) Stock Analysis
DELISTED 2016
What happened to Echo Therapeutics, Inc. (ECTE) stock?
Echo Therapeutics, Inc. (ECTE) no longer trades on public markets. It was delisted in July 2016. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Echo Therapeutics, Inc. (ECTE) trades at $0.0002. Echo Therapeutics, Inc. is focused on developing transdermal skin permeation and diagnostic medical devices. Their primary focus is a needle-free wireless continuous glucose monitoring (CGM) system. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for ECTE: ECTE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ECTE against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Echo Therapeutics, Inc. (ECTE) Healthcare & Pipeline Overview
Echo Therapeutics, Inc. is a medical device company specializing in transdermal drug delivery and diagnostic systems, particularly a needle-free continuous glucose monitoring (CGM) system. The company operates in the wearable-health consumer and diabetes outpatient markets, seeking to commercialize its technology through strategic licensing agreements.
What Is the Investment Thesis for ECTE?
Echo Therapeutics presents a speculative investment opportunity centered on the potential success of its needle-free CGM technology. The company's licensing agreements in key markets like South Korea and China offer exposure to high-growth diabetes care markets. However, the company's negative P/E ratio of -0.00 indicates it is not currently profitable, and the high beta of 6.78 suggests significant volatility. The absence of a dividend further emphasizes the speculative nature of this investment. The successful development and commercialization of the CGM system, along with effective management of partnerships, are critical for realizing value. Investors should carefully consider the risks associated with OTC-listed companies and the uncertainty surrounding regulatory approvals and market adoption of novel medical devices.
Based on FMP financials and quantitative analysis
ECTE Key Highlights
Developing a needle-free wireless continuous glucose monitoring (CGM) system.
- Licensing agreement with Ferndale Pharma Group, Inc. for skin preparation devices in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community.
- License agreement with Handok Pharmaceuticals Co., Ltd. to commercialize CGM in South Korea.
- License, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd for CGM in China, Hong Kong, Macau, and Taiwan.
- Beta of 6.78 indicates high volatility compared to the market.
Who Are ECTE's Competitors?
ECTE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DXCM DexCom, Inc. | $89.92 | +0.04% | $33.9B | 93 |
| ABT Abbott Laboratories | $114.26 | -0.15% | $198B | 70 |
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| BSX Boston Scientific Corporation | $52.01 | +3.05% | $77.3B | 80 |
| EW Edwards Lifesciences Corporation | $89.83 | -2.65% | $51.7B | 93 |
| STE STERIS plc | $236.91 | +1.95% | $24.0B | 85 |
| ZBH Zimmer Biomet Holdings, Inc. | $100.72 | -0.02% | $19.5B | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ECTE's Key Strengths?
Proprietary needle-free CGM technology.
- Strategic licensing agreements in key markets.
- Focus on a growing market (diabetes care).
- Potential for less invasive glucose monitoring.
What Are ECTE's Weaknesses?
Negative P/E ratio indicates unprofitability.
- High beta suggests significant volatility.
- Reliance on licensing partners for commercialization.
- Limited financial resources compared to larger competitors.
What Could Drive ECTE Stock Higher?
Potential regulatory approval of the CGM system in the European Union.
- Progress in commercializing the CGM system in South Korea through Handok Pharmaceuticals.
- Advancement in the development and commercialization of the CGM system in China, Hong Kong, Macau, and Taiwan through Medical Technologies Innovation Asia.
- Continued development of next-generation CGM technology.
What Are the Key Risks for ECTE?
Failure to obtain regulatory approval for the CGM system in key markets.
- Dependence on licensing partners for successful commercialization.
- Competition from established players in the diabetes care market.
- Technological obsolescence and the emergence of competing technologies.
- Limited financial resources and the need for additional funding.
What Are the Growth Opportunities for ECTE?
- Expansion into the European Union: Echo Therapeutics is currently developing its CGM system for use in hospitals within the European Union. Successful market entry in the EU could provide a significant revenue stream and establish the company's presence in a key healthcare market. The European market for diabetes monitoring devices is substantial, offering a significant growth opportunity if regulatory approvals are secured and the product is successfully commercialized. Timeline is dependent on regulatory approval.
- Penetration of the South Korean Market: The licensing agreement with Handok Pharmaceuticals Co., Ltd. provides Echo Therapeutics with access to the South Korean diabetes care market. South Korea has a growing population of individuals with diabetes, creating a strong demand for advanced monitoring solutions. Successful commercialization of the CGM system in South Korea could generate substantial revenue and establish a strong foothold in the Asian market. Timeline is dependent on Handok's commercialization efforts.
- Commercialization in China: The license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd offers Echo Therapeutics the opportunity to tap into the vast Chinese market. China has the largest diabetic population in the world, presenting a significant growth opportunity for CGM technologies. Successful development and commercialization of the CGM system in China, Hong Kong, Macau, and Taiwan could drive substantial revenue growth. Timeline is dependent on MTIA's development and commercialization efforts.
- Development of Next-Generation CGM Technology: Continuous innovation in CGM technology is crucial for maintaining a competitive edge. Echo Therapeutics could invest in developing next-generation CGM systems with improved accuracy, enhanced features, and greater user convenience. This could involve exploring new sensor technologies, data analytics capabilities, and integration with other wearable devices. Timeline is dependent on R&D investment and technological advancements.
- Strategic Partnerships and Acquisitions: Echo Therapeutics could pursue strategic partnerships or acquisitions to expand its product portfolio, access new markets, or acquire complementary technologies. Collaborating with other medical device companies or pharmaceutical companies could accelerate the development and commercialization of its CGM system and other related products. Timeline is dependent on strategic opportunities.
What Are ECTE's Competitive Advantages?
- Proprietary transdermal skin permeation technology.
- Patents protecting its needle-free CGM system.
- Strategic licensing agreements providing access to key markets.
- First-mover advantage in the needle-free CGM space (if successfully commercialized).
What Does ECTE Do?
Echo Therapeutics, Inc., founded in 1989 and headquartered in Iselin, New Jersey, is a medical device company focused on developing and commercializing its needle-free continuous glucose monitoring (CGM) system. The company's core technology revolves around transdermal skin permeation, aiming to provide a less invasive method for monitoring glucose levels in diabetic patients. Echo Therapeutics is currently developing a wireless CGM system intended for use in hospital settings within the European Union. Echo Therapeutics employs a licensing strategy to expand its market reach and commercialize its technologies. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. Additionally, Echo Therapeutics has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea. Furthermore, the company has a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. These partnerships are crucial for navigating regulatory landscapes and accessing diverse patient populations.
What Products and Services Does ECTE Offer?
- Develops transdermal skin permeation technologies.
- Focuses on diagnostic medical devices for wearable health.
- Creates solutions for the diabetes outpatient market.
- Developing a needle-free wireless continuous glucose monitoring (CGM) system.
- Seeks to commercialize its technologies through licensing agreements.
- Aims to provide less invasive methods for monitoring glucose levels.
How Does ECTE Make Money?
- Develops and patents transdermal drug delivery and diagnostic technologies.
- Out-licenses its technology to partners for commercialization in specific geographic regions.
- Generates revenue through licensing fees and potential royalties on product sales.
- Focuses on R&D and strategic partnerships rather than direct manufacturing and distribution.
What Industry Does ECTE Operate In?
Echo Therapeutics operates in the medical device industry, specifically targeting the diabetes care market. The competitive landscape includes established players like Medtronic and Abbott, as well as emerging companies focused on innovative CGM solutions. Echo Therapeutics aims to differentiate itself through its needle-free technology, potentially offering a more convenient and less invasive alternative to traditional CGM systems. The company's success will depend on its ability to navigate regulatory hurdles, secure market access, and effectively compete with established players.
Who Are ECTE's Key Customers?
- Hospitals and healthcare providers in the European Union (future target for CGM system).
- Diabetic patients in South Korea (through Handok Pharmaceuticals partnership).
- Diabetic patients in China, Hong Kong, Macau, and Taiwan (through Medical Technologies Innovation Asia partnership).
- Medical professionals using skin preparation devices (through Ferndale Pharma Group partnership).
Company Profile
Echo Therapeutics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Iselin, US. The company is led by CEO Alan W. Schoenbart CPA. ECTE has traded publicly since 2011.
Insider Activity
The most recent 12 insider filings for Echo Therapeutics, Inc. break down as 1 sales and 11 purchases. On net that is roughly 1.6M shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.
ECTE Financials
Bull Case vs Bear Case
Bull Case
- Proprietary needle-free CGM technology.
- Strategic licensing agreements in key markets.
- Focus on a growing market (diabetes care).
- Potential for less invasive glucose monitoring.
Bear Case
- Negative P/E ratio indicates unprofitability.
- High beta suggests significant volatility.
- Reliance on licensing partners for commercialization.
- Limited financial resources compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ECTE Latest News
No recent news available for ECTE.
Leadership: Alan W. Schoenbart CPA
CEO
Alan W. Schoenbart is the Chief Executive Officer of Echo Therapeutics, Inc. He is a Certified Public Accountant (CPA) with extensive experience in financial management and corporate leadership. His background likely includes experience in accounting, financial reporting, and strategic planning. His expertise is crucial for guiding Echo Therapeutics through its development and commercialization efforts.
Track Record: As CEO of Echo Therapeutics, Alan W. Schoenbart is responsible for overseeing the company's strategic direction and operations. His leadership is critical for navigating the regulatory landscape, managing partnerships, and securing funding for the company's research and development activities. His tenure has been focused on advancing the needle-free CGM technology and establishing licensing agreements to expand market reach.
ECTE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Echo Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher price volatility due to lower trading volumes.
- Potential for delisting or suspension of trading.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any material developments.
- Consult with a financial advisor before investing.
- Development of innovative needle-free CGM technology.
- Strategic licensing agreements with established partners.
- Experienced management team.
- Focus on a growing market (diabetes care).
- Headquarters located in Iselin, New Jersey.
Echo Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What happened to Echo Therapeutics, Inc. (ECTE) stock?
Echo Therapeutics, Inc. (ECTE) no longer trades on public markets. It was delisted in July 2016. The figures below are historical and are not a current quote.
Can I still buy ECTE shares?
No. ECTE stopped trading on public markets in July 2016, so the shares are not available through a broker. Anything you see quoted for ECTE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ECTE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Echo Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Echo Therapeutics, Inc. do?
Echo Therapeutics, Inc. is a medical device company focused on developing and commercializing its needle-free continuous glucose monitoring (CGM) system. The company's core technology revolves around transdermal skin permeation, aiming to provide a less invasive method for monitoring glucose levels in diabetic patients.
What are the main risks for ECTE?
The main risks for Echo Therapeutics include regulatory hurdles in obtaining approval for its CGM system, dependence on licensing partners for commercialization success, competition from established players in the diabetes care market, and the potential for technological obsolescence. Additionally, as an OTC-listed company, ECTE faces risks associated with limited financial disclosure, higher price volatility, and potential liquidity constraints. Investors should carefully assess these risks before investing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.